MAPT and Alzheimer disease: Participants who received lecanemab saw a greater frequency of amyloid-related imaging abnormalities (ARIA)-H (17.3% vs. 9.0%) and ARIA-E (12.6% vs. 1.7%), which is a significant adverse outcome.<h4>Conclusion</h4>Lecanemab has been shown to have an impact on the two primary pathophysiologic indicators of AD (Aβ and tau).